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for diabetic cardiovascular autonomic 
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Abstract 
Objectives: This study aimed to estimate the performance of diabetic cardiovascular autonomic neuropathy (DCAN) 
diagnostic tests in the absence of a gold standard.
Background: The DCAN prevalence is rapidly growing in all populations worldwide. No document has been 
reported about diagnostic performance for DCAN based on short‑term HRV without a gold standard.
Methods: We conducted a cross‑sectional study to perform diagnostic test in Chinese diabetic patients. A dataset 
contained 56 subjects who completed both the short‑term HRV test and Ewing’s test. Simultaneous inferences about 
the population prevalence and the performance of each diagnostic test were possible using the Bayesian approach.
Results: The HRV test had a high sensitivity (0.837 and 0.821 for independence model) and specificity (0.838 and 
0.797 for dependence model) to DCAN. In addition, the non‑inferiority test rejected the hypothesis that the perfor‑
mance of the HRV test was inferior to that of Ewing’s test (P < 0.05). The estimated DCAN prevalence in our study 
sample was more than 0.400.
Conclusion: Our findings provided evidence that short‑term HRV were used for the DCAN diagnostic test with a 
high sensitivity and specificity.
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Background
Diabetic cardiovascular autonomic neuropathy (DCAN) 
is one of the most overlooked of all serious complica-
tions of diabetes [1–3], which encompasses damage to 
the autonomic nerve fibers that innervate the heart and 
blood vessels, resulting in abnormalities in heart rate 
control and vascular dynamics [4]. DCAN is rapidly 
growing in all populations worldwide, particularly in the 
developing world [5]. DCAN may carry an increased risk 
of mortality. Patients with DCAN have an unfavorable 
cardiovascular risk profile, especially in terms of sudden 
death, indicating a higher risk of cardiovascular disease 
[5].
Ewing tests and spectral analysis of spontaneous heart 
rate variability (HRV) were two widely acceptable meth-
ods for cardiovascular autonomic function (CAF) test 
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[6, 7]. Ewing’s test, including five simple noninvasive 
cardiovascular autonomic reflex tests, had a high sensi-
tivity and specificity for CAF test, [8–11]. However, this 
test required personnel with specialized skills and was 
not readily available in general practice [10, 12]. Spec-
tral analysis of HRV had the advantage of quantitatively 
assessing cardiovascular autonomic activity, and it yields 
results that were similar to those produced by Ewing’s 
test [10–13]. Short-term HRV was simple, noninva-
sive, and reproducible so as to be easily applied in CAF 
tests in a large-scale sample [11–13]. Our previous study 
indicated that the short-term HRV indices had a signifi-
cant negative value correlated with DM, HT, and MS 
[14]. In general Chinese population, our previous stud-
ies evaluated the reference values of short-term HRV, 
and used these values to create diagnostic criteria for 
CAN [15]. Although Ewing’s test was acceptable for CAF 
test in clinical practice, there was no widely accepted a 
gold standard approach to DCAN diagnosis. Further-
more, we performed a diagnostic study in which Bayes-
ian approaches had been used to estimate diagnostic 
performance of short-term HRV test for CAN and non-
inferior tests provided evidence that this test was similar 
to Ewing’s test for CAN diagnosis in a general Chinese 
sample [16–18]. Interestingly, Bayesian statistics had 
been use to diagnostic performance of tests for diseases 
in the absence of a gold standard [19, 20]. In general, the 
Bayesian approach to inference about a generic param-
eter θ combines prior information about θ with the data 
to obtain the posterior distribution of θ, p(θ|data). Then, 
one can use the mean, median, or mode of this posterior 
distribution as an estimate of θ. Once one can obtain a 
sample from p(θ|data), a Monte Carlo based estimate of θ 
can be calculated.
Our previous studies focused on clinical analysis for 
CAN in general Chinese population, but not in dia-
betic patients [16]. However, no documents have been 
reported about short-term HRV test for CAN diagnosis 
without a gold standard in Chinese diabetic patients. The 
objective of this study was to estimate diagnostic per-
formance of short-term HRV test for DCAN using the 
Bayesian approach without a gold standard. Moreover, 
comparison of diagnostic performance of the two tests 
for DCAN was analyzed.
Methods
Study population
This study is a CAN factor survey carried out in a ran-
dom sample of the middle-aged Chinese population [14]. 
Participants that were simultaneously assessed CA func-
tion using both the short-term HRV and Ewing’s tests 
were recruited from department of endocrinology and 
metabolism and a healthy examination center of Huashan 
hospital. Survey participants with undiagnosed CAN, 
aged 30–80 years, were included in this study. More than 
100 subjects were invited to a screening visit between 
2011 and 2012. Some subjects were excluded from the 
study to eliminate potential confounding factors that 
may have influenced their CA function [14]. Briefly, the 
exclusion criteria were as follows: (1) history or findings 
of arrhythmia, and hyperthyroidism or hypothyroidism; 
(2) pregnancy or lactation; and/or (3) serious hepatic or 
renal dysfunctions. Of these subjects, complete baseline 
data were obtained for 88 of the participants. Finally, data 
from 56 dietetic patients have been used to analysis for 
DCAN diagnostic performance. Written consent was 
obtained from all patients before the study. This study 
was approved by the Ethics Committee of the Huashan 
Hospital, Shanghai, China.
Measurement
The subjects were interviewed for the documentation 
of medical histories and medication, history of smoking 
habits and laboratory assessment of cardiovascular dis-
ease risk factors. All study subjects underwent a com-
plete clinical baseline characteristics evaluation after 
an 8-hour fast, which included: (1) history and physical 
examination, (2) heart rate and blood pressure, (3) FPG 
and insulin, and (4) fasting plasma lipids. The FPG was 
quantified by the glucose oxidase procedure. Serum total 
cholesterol (TC), HDL cholesterol, TG levels, creatinine 
(Cr), and uric acid (UA) were measured by an enzymatic 
method with a chemical analyzer (Hitachi 7600-020, 
Tokyo, Japan). Low-density lipoprotein (LDL) cholesterol 
levels were calculated using the Friedewald formula. At 
the central laboratory in our hospital, the day-to-day and 
inter-assay coefficients of variation for all analyses were 
between 1 and 3 %.
Diagnostic tests
Ewing’s test for the detection of subclinical CAN was car-
ried out as previously described [6]. Briefly, HRV values 
were analyzed during three maneuvers: deep-breathing 
(DB), lying-to-standing (LS), and Valsalva (V) tests. The 
DB test consisted of six deep respiratory cycles in 1 min. 
The result of the DB test was expressed as the mean value 
for the ratio of maximal interval between two consecu-
tive R waves on the ECG (RR) during breathing out, over 
minimal RR during breathing in at each respiratory cycle. 
The result of the LS test was expressed as the ratio of 
the longest RR interval (about the 30th beat after stand-
ing up) over the shortest RR interval (about the 15th 
beat). The Valsalva test was performed three consecutive 
times, and the mean value for the Valsalva ratio (VR) was 
defined by the longest RR interval after Valsalva release 
over the shortest RR interval during the active phase of 
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Valsalva. Cardiac parasympathetic neuropathy was con-
sidered to be present when at least one test was abnor-
mal according to age. The other two tests investigated 
BP response to the LS test and to a standard handgrip 
test. Postural hypotension was assessed by measuring BP 
after 10  min in the recumbent position and again after 
1  min in the standing position. Postural hypotension 
was defined as a drop in SBP of ≥20  mmHg or in DBP 
of ≥10 mmHg. The handgrip test consisted of determin-
ing the maximal contraction with a dynamometer and 
then maintaining one-third of the maximal contraction 
for 5 min. An increase in DBP lower than 10 mmHg was 
considered to be abnormal. The three tests evaluating 
HRV are mainly dependent on parasympathetic control, 
whereas the other two tests evaluating BP response are 
mainly dependent on sympathetic activity.
The HRV values were measured non-invasively by 
power spectral analysis. Subjects were studied while 
awake in the supine position after 20 min of rest. Testing 
times were from 8:00 to 11:00 in the morning. A type-I 
FDP-1 HRV noninvasive detecting system was used with 
software version 2.0 (Department of Biomedical Engi-
neering of Fudan University, Shanghai, China). Electro-
cardiography, respiratory signals, and beat-to-beat blood 
pressure were continually and simultaneously recorded 
for 15 min through an electrosphygmograph transducer 
(HMX-3C placed on the radial artery of the dominant 
arm) and an instrument respiration sensor. The short-
term HRV analysis was performed for all subjects using 
a computer-aided examination and evaluation system for 
spectral analysis to investigate changes in autonomic reg-
ulation. The following HRV parameters were measured 
by frequency domain spectral analysis [10]: total power 
(TP), lower frequency (LF), normalization LF (LFn), high 
frequency (HF), and normalization HF (HFn). The TP is 
the variance of the normal-to-normal interval (NN) over 
a temporal segment; HF is closely related to vagal activ-
ity. The LF/HF ratio was calculated because it is consid-
ered to reflect sympatho-vagal balance or sympathetic 
modulation [12].
Definition
The HT was defined as a repeatedly elevated blood pres-
sure exceeding 140 over 90  mmHg—a systolic pressure 
above 140 or a diastolic pressure above 90. The DM was 
diagnosed by demonstrating any one of the following: 
(1) FPG level ≥7.0 mol/l; (2) plasma glucose ≥11.1 mol/l 
2 h after a 75 g oral glucose tolerance test (OGTT); (3) 
symptoms of hyperglycemia and casual plasma glu-
cose ≥11.1 mol/l and (4) glycated hemoglobin (HbA1C) 
≥6.5 %. The BMI was calculated by weight in kilograms 
divided by the square of height in meters. Metabolic syn-
drome was diagnosed in individuals who met three or 
more criteria of the updated National Cholesterol Edu-
cation Program/Adult Treatment Panel III (WHO West-
ern Pacific Region obesity criteria) [21]. In this study, 
CAN was diagnosed based on at least two abnormal CA 
reflex test results (based on Ewing’s test model or HRV 
test model) [11, 15]. DCAN was diagnosed in diabetic 
patients with CAN.
Statistical analysis
The Kolmogorov–Smirnov (K–S) test was used to deter-
mine whether continuous variables followed a normal 
distribution. Variables that were not normally distrib-
uted were log-transformed to approximate normal dis-
tribution for analysis. The results are expressed as the 
mean ± standard deviation or median, unless otherwise 
stated. Pearson and Spearman analytical methods were 
employed for correlation analysis of two variables. In 
general, we report skewed data in tables with 2.5th and 
97.5th percentiles or median, however, in this study we 
reported skewed data involved in indices of HRV with 
mean and SD format because HRV parameters often 
were presented with the format in other studies.
We used a Bayesian latent class model to estimate the 
sensitivity and specificity of the HRV test and/or Ewing’s 
test for DCAN in the absence of a gold standard, as 
described by Branscum et al. [22]. The latent class anal-
ysis allows the characterization of a discrete latent class 
(here, the true disease status) by discrete observed vari-
ables. In this model, both tests are equally considered as 
imperfect. There are unknown parameters about which 
inference must be made: the DCAN population preva-
lence, and the sensitivity and specificity of each of the two 
tests. The Bayesian approach can simultaneously estimate 
all five unknown parameters. These methods proceed 
in two steps: first, a prior distribution summarizes the 
available pre-experimental information about the param-
eters. Subsequently, the prior distribution is updated via 
Bayes’ theorem to a posterior distribution, using the data 
and the usual multinomial likelihood function. Marginal 
posterior densities can be derived for each parameter by 
integration, from which 95 % marginal posterior credible 
intervals can be calculated. Since the integration here is 
analytically intractable, the Gibbs sampler, a Monte Carlo 
approach to calculating marginal densities, is employed. 
The above methods allow for simultaneous inferences 
to be made for all unknown parameters, which take full 
advantage of all the information contained in the data, 
as well as formally incorporate prior information, when 
available (see Additional file 1). A minimum sample size 
estimation for this diagnostic performance analysis was 
50 subjects by using sample size estimation formula: 
N  =  Z2Sen(1  −  Sen)/deta2  +  Z2Spe(1  −  Spe)/deta2; 
here, Z derived form alpha level (0.05 in this study), Sen 
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(sensitivity) and Spe (specificity) were set to 0.85, respec-
tively; deta was set to 0.10–0.20 in this study. Data were 
analyzed using SPSS16.0 (USA) and WinBUGS.14 for the 
Bayesian analysis.
Results
The baseline characteristics of the 56 subjects are listed 
in Table 1. The entire sample included 24 males and 32 
females (mean age, 59.21 ± 8.22 years). The majority of 
subjects had never smoked (75.37 %), and the prevalence 
of HT and MS were 64.29  % and 57.14  % in the entire 
sample, respectively. The most of demographic param-
eters, parameters of blood glucose, lipid profiles, and 
medical histories of diabetic patients without CAN were 
similar to those of patients with DCAN (P >0.05 for all). 
However, there were significantly greater levels of SBP 
and FPG in patients with DCAN as compared with those 
of diabetic patients without CAN, respectively (P = 0.013 
for SBP and P =  0.025 for FPG). Furthermore, patients 
with DCAN have longer duration of DM and PH com-
pared to those of diabetic patients without CAN, respec-
tively (P = 0.026 for DM duration and P = 0.001 for PH 
duration).
Of the 56 subjects in the external dataset, 27 and 34 
subjects were diagnosed with CAN using the HRV test 
alone and Ewing’s test alone, respectively (Table 2). Using 
both tests, 21 subjects were diagnosed with CAN, while 
16 subjects were diagnosed free of CAN.
Table 1 Baseline characteristics of subject
WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, TC serum total cholesterol, TG triglyceride, UA uric acid, 
HDL high-density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, HR heart rate, TP total power of variance, LF low frequency, HF high frequency, MS 
metabolic syndrome, HT hypertension, DM diabetes
Variable Total sample non-DCAN DCAN P value
Demographic information
 N 56 22 34
 Age (years) 59.21 ± 8.22 59.82 ± 9.7 58.91 ± 7.64 0.769
 Gender male (%) 24 (42.86 %) 10 (45.45 %) 19 (55.88 %) 0.340
 Height (cm) 164.32 ± 6.74 163.82 ± 6.69 164.57 ± 6.89 0.767
 Weight (kg) 63.88 ± 9.61 63.91 ± 10.29 63.87 ± 9.5 0.991
 WC (cm) 84.29 ± 6.73 82.82 ± 6.26 85 ± 6.97 0.385
 SBP (mmHg) 125.85 ± 10.62 120.31 ± 10.62 129.26 ± 11.22 0.013
 DBP (mmHg) 81.23 ± 9.59 79.26 ± 8.79 82.68 ± 9.39 0.156
Laboratory assays
 FPG (mmol/L) 6.84 ± 1.93 6.56 ± 1.78 7.02 ± 2.01 0.025
 TC (mmol/L) 5.35 ± 1.05 5.2 ± 1.01 5.45 ± 1.08 0.365
 TG (mmol/L) 1.86 ± 1.07 1.78 ± 1.02 1.91 ± 1.09 0.452
 HDL (mmol/L) 1.30 ± 0.30 1.27 ± 0.28 1.32 ± 0.31 0.619
 LDL (mmol/L) 3.14 ± 0.79 3 ± 0.71 3.23 ± 0.89 0.767
 UA (μmol/L) 292.34 ± 82.65 276.62 ± 79.65 302.51 ± 85.65 0.477
HRV measurement
 HR (bpm) 73.62 ± 11.09 71.3 ± 7.98 74.81 ± 12.31 0.265
 TP (ms2) 731.49 ± 895.49 832.61 ± 814.17 679.56 ± 941.02 0.550
 LF (ms2) 144.85 ± 245.48 155.49 ± 228.32 139.38 ± 256.73 0.819
 LFnu 16.82 ± 9.81 17.13 ± 7.25 16.66 ± 10.99 0.867
 HF (ms2) 191.28 ± 460.81 204.79 ± 283.98 184.33 ± 532.87 0.877
 HFnu 20.08 ± 15.01 20.66 ± 14.24 19.78 ± 15.57 0.837
 LF/HF 1.33 ± 1.15 1.46 ± 1.33 1.26 ± 1.05 0.554
Medical history
 Smoking yes (%) 15 (41.67 %) 5 (22.73 %) 10 (29.41 %) 0.956
 HT yes (%) 36 (64.29 %) 13 (59.09 %) 23 (67.65 %) 0.471
 MS yes (%) 32 (57.14 %) 11 (50.00 %) 21 (61.76 %) 0.856
 DM duration 7.3 ± 1.45 6.55 ± 1.60 7.66 ± 1.28 0.026
 PH duration 4.4 ± 1.38 1.86 ± 1.03 5.61 ± 1.34 0.001
Page 5 of 8Chen et al. Diabetol Metab Syndr  (2015) 7:74 
Prior distributions of Bayesian analysis
Prior distributions can be estimated based on a review 
of the literature and/or expert opinion in the absence of 
data. Published evaluations of Ewing’s test indicated a 
good sensitivity (0.7–1.0) and specificity (0.7–1.0), which 
has a beta distribution with parameters (α, β) [10–12, 
23]. Previous studies demonstrated that performances of 
HRV to assess CA activity were similar to those of Ewing’s 
test [12, 24, 25]. We formed a hypothesis for the short-
term HRV test with a sensitivity and specificity of a beta 
distribution between 0.7 and 1.0, respectively. Finally, 
the prior distribution of prevalence was considered beta 
between 0.1 and 0.5 [10, 12, 26]. The same parameters of 
prior distribution for the HRV test alone were estimated 
in the total sample, and in the DM, HT, and MS patients. 
The two tests used here relied on the analysis of HRV 
attributes. As recommended by Dendukuri et al. [27], in 
the main analysis, the tests were also considered a con-
ditionally independent model. The particular beta prior 
density for each test parameter was selected by matching 
the center of the range with the mean of the beta distri-
bution, given by α/(α + β), and matching the variance of 
the beta distribution, given by the square root of (αβ)/
((α + β)2(α + β+1)) with one quarter of the total range.
Bayesian estimation of diagnostic test
When both tests were combined with the conditional 
independence model, the median posterior DCAN prev-
alence was 0.429 (95 % CI, 0.278–0.590, Table 3), and the 
median posterior sensitivity and specificity of the HRV 
test were 0.837 (95  % CI, 0.681–0.948) and 0.838 (95  % 
CI, 0.696–0.941), respectively. There was an apparently 
higher sensitivity (0.878) but a lower specificity (0.745) of 
Ewing’s test, compared with those of the HRV test. When 
both tests were combined with the conditional depend-
ence model, the median posterior DCAN prevalence was 
0.403 (95  % CI, 0.222–0.591), and the median posterior 
sensitivity and specificity of the HRV test were 0.821 
(95 % CI, 0.626–0.950) and 0.797 (95 % CI, 0.636–0.927), 
respectively. There were modest correlations between the 
HRV test and Ewing’s test (ρP = 0.335 and ρN = 0.344).
Non-inferiority analysis for diagnostic parameters
Similar parameters of the HRV for DCAN were found 
(Table  3). Generally, the median posterior sensitivi-
ties and specificities of the HRV test were over 80  % in 
all models. Higher sensitivities and lower specificities 
of Ewing’s test were found in all models, compared with 
those of the HRV test. The posterior Youden indices of 
the HRV test were higher than those of Ewing’s test in all 
models. In combined tests, we compared the parameters 
(mean sensitivity, mean specificity, accuracy, PPV and 
NPV) for performance of both diagnostic tests by using 
a non-inferiority test that rejected the hypothesis that 
the diagnostic performance of the HRV test was infe-
rior to that of Ewing’s test (P < 0.05 for all parameters in 
two models, Table 4), suggesting that the performance of 
short-term HRV test was similar to Ewing’s test in diag-
nosis of DCAN.
Table 2 Results of  short-term HRV and  Ewing’s’ test 
for cardiovascular autonomic neuropathy in 56 subjects
Model Ewing’s’ test Total
+ −
HRV test + 21 6 27
− 13 16 29
Total 34 22 56
Table 3 Marginal prior and posterior medians and lower and upper limits of the posterior equally tailed 95 % credible 
interval for parameters of diagnostic tests
Date represent to be mean and 95 % CI, PPV positive predictive value, NPV negative predictive value, ρP correlation coefficients of sensitivities of two tests, ρN 
correlation coefficients of specificities of two tests
Variables Prior information Both tests combined (independence) Both tests combined (dependent)
HRV test Ewing’s test HRV test Ewing’s test
Prevalence 0.300 (0.120–0.480) 0.429 (0.278–0.59) 0.403 (0.222–0.591)
Sensitivity 0.850 (0.720–0.980) 0.837 (0.681–0.948) 0.878 (0.748–0.962) 0.821 (0.626–0.95) 0.852 (0.698–0.956)
Specificity 0.850 (0.720–0.980) 0.837 (0.696–0.941) 0.745 (0.591–0.891) 0.797 (0.636–0.927) 0.695 (0.529–0.888)
Accuracy 0.850 (0.720–0.980) 0.835 (0.727–0.919) 0.810 (0.705–0.9) 0.807 (0.666–0.911) 0.774 (0.647–0.894)
PPV 0.708 (0.260–0.978) 0.796 (0.582–0.934) 0.720 (0.497–0.902) 0.733 (0.451–0.916) 0.651 (0.375–0.901)
NPV 0.923 (0.950–0.982) 0.874 (0.69–0.967) 0.892 (0.743–0.97) 0.873 (0.639–0.972) 0.876 (0.71–0.970)
ρP 0.335 (0.017–0.838)
ρN 0.344 (0.016–0.838)
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Discussion
A cross-sectional study was conducted to evaluate diag-
nostic performance of short-term HRV for DCAN in 
Chinese diabetic patients. Short-term HRV was a sim-
ple, noninvasive, and reproducible test for CAF evalua-
tion and was more suitable for clinical application in CAF 
test. In this study, it is very important for us to under-
stand that the HRV test and Ewing’s test are similar diag-
nostic tests. Additionally, we paid attention on no widely 
accepted a gold standard diagnostic criteria for DCAN 
in clinical practice, and Bayesian analysis to be applied 
for estimation of diagnostic parameters in the absence 
of a gold standard. More importantly, it is the first study, 
using Bayesian approaches in the absence of a gold stand-
ard, to estimate the diagnostic performance of short-term 
HRV for DCAN in Chinese diabetic patients.
An interesting finding is that the diagnostic test for 
DCAN based on the short-term HRV showed a high 
sensitivity and specificity. In our study sample, the esti-
mated median sensitivities and specificities of the HRV 
test for DCAN were up to 0.800 in all models. The 
median sensitivities was 0.837 and 0.821 in independ-
ence and dependence models, respectively. Specially, 
the high median specificities (0.878 and 0.852 for both 
model, respectively) was reported, which was important 
for diagnosis of DCAN in clinical practice. Our previous 
study conducted Bayesian analysis for CAN in diabetic 
subgroup under HRV alone model to show this test hav-
ing high sensitivity (0.843) and specificity (0.866). Under 
both tests combined model, high sensitivities (0.800-
0.822) and specificities (0.812–0.852) were also reported 
for this test to diagnose CAN in general Chinese popula-
tion. In this study, we could find that the mean values of 
short-term HRV indices were higher in patients without 
DCAN as compared to patients with DCAN. However, 
there were no differences in HRV indices between the 
two groups. These results were not consistent with previ-
ous findings in other literature. This was partly because 
the description statistics of raw data of HRV indices 
showed to those parameters with large variances in our 
study. Additionally, this may be our study with a moder-
ate sample size. However, we set the reference value using 
the 5th percentiles and combined at least two indices 
value for diagnostic criteria of CAN. The diagnostic crite-
ria have enough power to determine outcomes, although 
there were no differences in HRV indices between the 
two groups. Moreover, the results of Bayesian analysis 
supported the fact that short-term HRV for diagnosis of 
CAN have high sensitivity and specificity. More impor-
tantly, future studies with design well will test the influ-
ence of heart rate. Our results provided evidence that 
the HRV test is an efficient test for diagnosis of DCAN in 
clinical practice.
It was very important to evaluate the performance 
of the HRV test in both tests combined with the inde-
pendence and dependence models using the Bayesian 
approach. The combined tests allowed for sharper infer-
ences to be drawn [28]. Studies were generally performed 
to evaluate the performance of new diagnostic tests 
using Ewing’s as a reference, however, the test was actu-
ally not a gold standard. Using the Bayesian approach, in 
the absence of a gold standard, simultaneous inferences 
about the performance of each diagnostic test are pos-
sible. Additionally, Bayesian estimation of the param-
eters of a diagnostic test needs prior information. In this 
study, precise and accurate posterior parameters should 
be derived from appropriate prior parameters. This is 
more suitable for clinical research because it is easier for 
experts with relevant clinical experience to estimate prior 
parameters accurately.
A non-inferiority test indicated that the most of param-
eters was not inferior to that of Ewing’s test, except 
sensitivity parameter under both test combined with 
dependence model. These findings provided evidence 
that the HRV test was not inferior to Ewing’s test for 
DCAN diagnosis. To our knowledge, this is the first study 
Table 4 Comparison of performance of HRV test and Ewing’s test in combined both tests
Non-inferiority test to test the hypothesis of performance of HRV test inferior to Ewing’s test; delta >0 is the non-inferiority margin of clinical interest, which is set as 
quarter of value of parameter of Ewing’s test in this study. PPV positive predictive value, NPV negative predictive value
Parameter Both tests combined (independence) Both tests combined (dependence)
HRV test Ewing’s test P value HRV test Ewing’s test P value
Mean SE Mean SE Mean SE Mean SE
Sensitivity 0.830 0.070 0.872 0.056 0.035 0.812 0.086 0.845 0.066 0.086
Specificity 0.833 0.063 0.744 0.077 0.000 0.792 0.075 0.700 0.091 0.006
Accuracy 0.832 0.049 0.808 0.049 0.001 0.802 0.063 0.772 0.062 0.011
PPV 0.786 0.091 0.715 0.104 0.002 0.720 0.119 0.649 0.136 0.016
NPV 0.862 0.072 0.882 0.059 0.005 0.853 0.089 0.866 0.068 0.019
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to have reported that in the absence of a gold stand-
ard, short-term HRV test for DCAN diagnosis had high 
sensitivity and specificity. Previously, Ewing’s test was a 
widely acceptable test for CAF evolution to be applied in 
DCAN diagnosis. Therefore, in this study, our finding is 
of importance to the clinical practice of DCAN diagnosis 
in diabetic patients.
In our study sample, under both tests models, estimated 
median prevalence of DCAN was more than 0.400. In our 
previous study, under HRV alone model, its prevalence 
was estimated at 0.292 in diabetic patients. Laitinen et al. 
[29] reported that the prevalence of parasympathetic dys-
function was 25 % in subjects with central obesity in per-
sons with impaired glucose tolerance. Additionally, the 
estimated CAN prevalence in diabetic patients was found 
to be 20–50  % in other studies [10, 11], indicating that 
our result was consistent with these studies. In our study 
sample, under the HRV test alone, CAN was estimated 
at 0.149 in the general population, suggesting that CAN 
was more frequent in diabetic patients. Our findings sup-
ported evidence that CAN has become a serious public 
problem in China. A higher prevalence of this disease 
was found in special subgroups.
Several limitations of this study warrant comment. This 
study does not cover age groups other than 30–80 years. 
Additionally, a cross-sectional study for the determina-
tion of diagnostic test requires a larger sample size and 
more geographic representations. Furthermore, our find-
ings need to be verified by future multiple centers stud-
ies and/or follow-up studies. Finally, it is important to 
mention that our study was performed on Chinese indi-
viduals, and our findings may not be relevant to people of 
other ethnicities.
In conclusion, this study provided evidence that short-
term HRV test has a high sensitivity and specificity for 
DCAN diagnosis, and that the HRV test was not inferior 
to the traditional Ewing’s test for DCAN. The estimated 
DCAN prevalence was high in diabetic patients. DCAN 
requires strategies to prevent and treat the disease 
(Additional file 1).
Strengths and limitations of this study
1. The first study to evaluate performance of diabetic 
cardiovascular autonomic neuropathy diagnosis 
based on short-term heart rate variability test by 
using Bayesian analysis without a gold standard
2. Comparison of performance of diagnosis based on 
short-term heart rate variability test and Ewing’s test 
by using non-inferiority test
3. Data interpretation and analysis be applied in Chi-
nese population, but lack of evidence to applied in 
other areas or ethnics
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